4-碘基-3-硝基苯甲醚 | 58755-70-7

• 物质功能分类: 有机原料 - 醚类化合物及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-碘基-3-硝基苯甲醚
• 中文别名: 3-硝基-4-碘苯甲醚；2-碘-5-甲氧基硝基苯；4-碘-3-硝基苯甲醚
• 英文名称: 1-iodo-4-methoxy-2-nitrobenzene
• 英文别名: 4-iodo-3-nitroanisole；2-iodo-5-methoxynitrobenzene；2-nitro-4-methoxyiodobenzene；4-iodo-3-nitroanisol；1-iodo-2-nitro-4-methoxybenzene
• CAS: 58755-70-7
• 化学式: C₇H₆INO₃
• mdl: MFCD00024195
• 分子量: 279.034
• InChiKey: JWZODIRSJJQOKY-UHFFFAOYSA-N

物化性质

• 熔点：
  61-62°C
• 沸点：
  173 °C(Press: 0.9 Torr)
• 密度：
  1.893
• 稳定性/保质期：

  避免接触光线和氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT, LIGHT SENSITIVE
• 安全说明：
  S26,S36/37/39
• 海关编码：
  2909309090
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  在密封的贮藏器中，应放置于阴凉、干燥处避光保存。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 4-Iodo-3-nitroanisole
CAS-No. : 58755-70-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
S-phrase(s) none
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C7H6INO3
Molecular Weight : 279,03 g/mol
Component Concentration
4-Iodo-3-nitroanisole
CAS-No. 58755-70-7 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen iodide
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 61 - 62 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,162
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-碘基-3-硝基苯甲醚 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 盐酸 、 N-碘代丁二酰亚胺 、 四丁基氟化铵 、 铁粉 、 溶剂黄146 、 三乙胺 、 sodium nitrite 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 为溶剂， 反应 11.5h， 生成 (7-ethynyl-6-methoxy-2H-indazol-3-yl)-(3,4,5-trimethoxyphenyl)methanone
  参考文献：
  名称：

  Potent Antitubulin Tumor Cell Cytotoxins Based on 3-Aroyl Indazoles

  摘要：

  A series of 3-aroyl indazoles was synthesized. Modification of the C-7 position resulted in a significant structure-activity relationship (SAR) with acetylene modifications conferring unusual potency in a tumor cell cytotoxicity assay. The most potent compounds exceeded the activity of combretastatin A4 (CA-4), showing single digit nM IC50 values against all cell lines tested including those with known efflux resistance pumps. The inhibition of in vitro tubulin polymerization was comparable to CA-4, consistent with tubulin being the target for these compounds. Competition binding experiments employing [H-3]colchicine and purified tubulins demonstrated that the compound specifically binds to the colchicine site.

  DOI：

  10.1021/jm061348t
• 作为产物：
  描述：

  3-硝基苯甲醚 在 吡啶 、 碘 、 硝酸 作用下， 生成 4-碘基-3-硝基苯甲醚
  参考文献：
  名称：

  THE IODINATION OF PHENOL AND CRESOL ETHERS

  摘要：

  DOI：

  10.1021/ja01367a042
• 作为试剂：
  描述：

  2-溴-6-氟苯甲酸 在 2-羟基-5-溴吡啶 、 4-二甲氨基吡啶 、 potassium dihydrogenphosphate 、 六氟异丙醇 、 硫酸 、 palladium 10% on activated carbon 、 4-碘基-3-硝基苯甲醚 、 氢气 、 palladium diacetate 、 magnesium sulfate 、 三乙胺 、 三(邻甲基苯基)磷 、 silver carbonate 、 三氟乙酸 、 N,N'-二异丙基碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 90.0 ℃ 、101.33 kPa 条件下， 反应 59.0h， 生成
  参考文献：
  名称：

  形式 C–H/C–I 复分解：使用芳基碘化物对苯胺进行位点选择性 C–H 碘化

  摘要：

  官能团复分解有可能为 C-H 官能化提供温和的反应条件。本文报道了使用 2-硝基苯基碘化物作为温和碘化试剂通过形式 C(sp 2 )–H/C(sp 2 )–I 复分解对苯胺衍生物进行间位和邻位 C-H碘化的方案。这些协议导致了一系列有价值的碘化苯胺衍生物的生产。这些结果证明了利用富电子化合物开发新型位点选择性 C-H 活化反应的潜力，因为温和的试剂通常可用于官能团复分解反应。

  DOI：

  10.1021/acs.orglett.2c01283

文献信息

• NOVEL INHIBITORS OF BETA-LACTAMASE
  申请人：Dininno Frank

  公开号：US20100279983A1

  公开（公告）日：2010-11-04

  This invention provides novel β-lactamase inhibitors of the aryl- and heteroarylsulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammonium groups. The compounds inhibit three classes of β-lactamases and synergize the antibacterial effects of β-lactam antibiotics (e.g., imipenem and ceftazidime) against those micro-organisms normally resistant to the β-lactam antibiotics as a result of the presence of the β-lactamases. Formula (I) or pharmaceutically acceptable salt thereof.

  这项发明提供了一种新型的β-内酰胺酶抑制剂，属于芳基和杂芳基磺酰胺基甲基膦酸单酯类，具有基于氮的阳离子或季铵基团。这些化合物抑制三类β-内酰胺酶，并增强β-内酰胺类抗生素（如亚胺培南和头孢他啶）对那些通常对β-内酰胺类抗生素具有抗药性的微生物的抗菌效果，这是由于β-内酰胺酶的存在。公式（I）或其药学上可接受的盐。
• [EN] BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE<br/>[FR] DERIVES D'AMIDE HETEROARYLE BENZOCONDENSE DE THIENOPYRIDINES UTILISEES EN TANT QU'AGENTS THERAPEUTIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES D'UTILISATION ASSOCIES
  申请人：PFIZER

  公开号：WO2003106462A1

  公开（公告）日：2003-12-24

  The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

  该发明涉及由公式I表示的化合物，以及这些化合物的前药或代谢物，或者这些化合物的药用可接受的盐或溶剂化合物，所述前药和代谢物，其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给予公式I化合物来治疗哺乳动物的增殖过度性疾病的方法。
• [EN] BENZIMIDAZOLE DERIVATIVES<br/>[FR] DERIVES BENZIMIDAZOLE
  申请人：NOVARTIS AG

  公开号：WO2005068433A1

  公开（公告）日：2005-07-28

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof; wherein R1-R7 are as disclosed in the specification and pharmaceutical uses thereof.

  公式(I)的化合物或其药物可接受的盐或前药酯；其中R1-R7如说明书所述，及其药物用途。
• Efficient Asymmetric Synthesis of Biologically Important Tryptophan Analogues via a Palladium-Mediated Heteroannulation Reaction
  作者：Chunrong Ma、Xiaoxiang Liu、Xiaoyan Li、Judith Flippen-Anderson、Shu Yu、James M. Cook

  DOI：10.1021/jo001679s

  日期：2001.6.1

  A novel and concise synthesis of optically active tryptophan derivatives was developed via a palladium-catalyzed heteroannulation reaction of substituted o-iodoanilines with an internal alkyne. The required internal alkyne 14a or 25 was prepared in greater than 96% de via alkylation of the Schöllkopf chiral auxiliary 19 employing diphenyl phosphate as the leaving group. The Schöllkopf chiral auxiliary

  通过钯催化的取代的邻碘苯胺与内部炔烃的杂环化反应，开发了一种新颖，简洁的光学活性色氨酸衍生物。通过使用磷酸二苯酯作为离去基团的Schöllkopf手性助剂19的烷基化，以大于96％的de制备所需的内部炔烃14a或25。在这里选择Schöllkopf手性助剂来制备L-色氨酸可从D-缬氨酸获得，而天然产物全合成所需的D-异构体则来自廉价的L-缬氨酸（300克规模）。钯催化的异环反应的应用扩展到了L-异色氨酸38和L-苯并[f]色氨酸39的首次不对称合成。更重要的是，按照该方案大规模（＞ 300g）制备了光学纯的6-甲氧基-D-色氨酸62。当与不对称的Pictet-Spengler反应结合时，这应该允许进入许多A环氧化的吲哚生物碱。另外，使用该钯介导的方法，以43％的总收率实现了Tryprostatin A（9a）改进的总合成。
• A General Copper Catalyst for Photoredox Transformations of Organic Halides
  作者：Bastien Michelet、Christopher Deldaele、Sofia Kajouj、Cécile Moucheron、Gwilherm Evano

  DOI：10.1021/acs.orglett.7b01518

  日期：2017.7.7

  irradiation in the presence of catalytic amounts of [(DPEphos)(bcp)Cu]PF6 and an amine, a range of unactivated aryl and alkyl halides were shown to be smoothly activated through a rare Cu(I)/Cu(I)*/Cu(0) catalytic cycle. This complex efficiently catalyzes a series of radical processes, including reductions, cyclizations, and direct arylation of arenes.

  报道了用于有机卤化物的光氧化还原转化的广泛适用的铜催化剂。在可见光照射下，在催化量的[（DPEphos）（bcp）Cu] PF 6和胺的存在下，未活化的芳基卤化物和烷基卤化物通过稀有的Cu（I）/ Cu（ I）* / Cu（0）催化循环。这种络合物有效地催化了一系列自由基过程，包括芳烃的还原，环化和直接芳基化。